The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better

Mhaimeed, Omar; Burney, Zain A; Schott, Stacey L; Kohli, Payal; Marvel, Francoise A; Martin, Seth S

doi:10.1016/j.ajpc.2024.100649

Cited by 14 publications

(1 citation statement)

References 97 publications

(131 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In which therapeutic decisions must change according to whether the levels of LDL-C intensify or decrease. LDL-C evaluated using precise technique [ 13 , 14 ]. For all this, the correct determination of LDL-C by different recommended methods is essential.…”

Section: Introductionmentioning

confidence: 99%

Comparison between the Friedewald, Martin and Sampson Equations and LDL-C Quantification by Ultracentrifugation in a Mexican Population

Fuentevilla-Álvarez,

Soto,

Valdivia

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Low-density lipoprotein cholesterol (LDL-C), which makes up about 70% of the cholesterol in the blood, is critical in the formation of arteriosclerotic plaques, increasing the risk of heart disease. LDL-C levels are estimated using Friedewald, Martin and Sampson equations, though they have limitations with high triglycerides. Our aim is to compare the effectiveness of these equations versus the ultracentrifugation technique in individuals with and without dyslipidemia and identify precision. There were 113 participants, 59 healthy controls and 54 dyslipidemic patients. Samples were collected after fasting. LDL-C was estimated using the Friedewald, Martin and Sampson equations. The purified LDL-C, ultracentrifugated and dialysized control group without dyslipidemia vs. patients with coronary artery disease (CAD) showed differences in age, HDL-C, triglycerides and glucose non-HDL-C (p = 0.001 in all). There were correlations in CGWD between ultracentrifugation and Sampson R-squared (R2) = 0.791. In the dyslipidemia control group, ultracentrifugation and Friedewald R2 = 0.911. In patients with CAD, correlation between ultracentrifugation and Sampson R2 = 0.892; Bland–Altman confirmed agreement in controls without dyslipidemia. The Martin and Sampson equations are interchangeable with ultracentrifugation. Conclusion: The role of LDL analysis using precise techniques is necessary to obtain better control of disease outcomes after the use of precise therapies and suggests verifying its importance through clinical trials.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison between the Friedewald, Martin and Sampson Equations and LDL-C Quantification by Ultracentrifugation in a Mexican Population

Fuentevilla-Álvarez,

Soto,

Valdivia

et al. 2024

Diagnostics

View full text Add to dashboard Cite

show abstract

Sex differences in LDL‐C reduction response to evolocumab: A propensity score matching analysis

He,

Wei,

Huang

et al. 2024

Pharmacotherapy

View full text Add to dashboard Cite

BackgroundProprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have been shown to improve cardiovascular outcomes by reducing low‐density lipoprotein cholesterol (LDL‐C). However, sex differences in the efficacy of evolocumab remain unclear. This study aimed to investigate sex differences in the efficacy of evolocumab using real‐world data.MethodData were collected from the First Affiliated Hospital of Guangxi Medical University. A total of 416 eligible patients were selected from 1463 patients treated with evolocumab for secondary prevention. Clinical data, including individual characteristics and lipids profiles, were recorded. Propensity score matching (PSM) was used to control for potential confounders, with covariates including age, body mass index, smoking status, and diabetes. All eligible participants were propensity‐matched 1:1 for female versus male with a match tolerance of 0.02. The efficacy of evolocumab in females and males was compared by PSM‐adjusted analysis.ResultsIn the PSM analysis, a significant difference was found in the relative percentage reduction of LDL‐C between females and males (−42.7% vs. −54.4%, p < 0.001). In addition, the absolute LDL‐C reduction was lower in females compared to males (interquartile range: −1.5 [−2.2, −0.8] mmol/L vs. −1.9 [−2.5, −1.0] mmol/L, p = 0.018). The rate of target LDL‐C attainment was lower in females than in males after treatment with evolocumab (21.6% vs. 39.8%, p = 0.009).ConclusionThese results suggest that males have a better response to evolocumab in term of LDL‐C reduction compared to females.

show abstract

Ezetimibe use and mortality after myocardial infarction: A nationwide cohort study

Kytö,

Tornio

2024

American Journal of Preventive Cardiology

View full text Add to dashboard Cite

The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better

Cited by 14 publications

References 97 publications

Comparison between the Friedewald, Martin and Sampson Equations and LDL-C Quantification by Ultracentrifugation in a Mexican Population

Comparison between the Friedewald, Martin and Sampson Equations and LDL-C Quantification by Ultracentrifugation in a Mexican Population

Sex differences in LDL‐C reduction response to evolocumab: A propensity score matching analysis

Ezetimibe use and mortality after myocardial infarction: A nationwide cohort study

Contact Info

Product

Resources

About